Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
IMM01-STEM Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
IMM01-STEM: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
CLPH-211 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
CLPH-211: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Radspherin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Radspherin: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
CNP-104 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
CNP-104: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Donor Derived HIV-Specific T-cells (DD HST-NEETs)(Children's National Research Institute): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence.
8 min read
BIIB-091 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
BIIB-091: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Lifirafenib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Lifirafenib: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Timolumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Timolumab: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
11C-methionine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
11C-methionine: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
Niferidil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Niferidil: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Arvidal Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Arvidal: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
TEV-53408 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
TEV-53408: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.